Arrowhead Research Corp. (NASDAQ:ARWR) traded up 4.2% during trading on Tuesday . The stock traded as high as $7.59 and last traded at $7.38, with a volume of 485,419 shares changing hands. The stock had previously closed at $7.08.

Several equities research analysts have recently commented on the stock. Piper Jaffray Cos. reduced their price target on shares of Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating for the company in a report on Wednesday, August 10th. Chardan Capital restated a “buy” rating and issued a $10.00 price target on shares of Arrowhead Research Corp. in a report on Wednesday, September 7th. William Blair assumed coverage on shares of Arrowhead Research Corp. in a report on Friday, August 19th. They issued an “outperform” rating for the company. Finally, Cantor Fitzgerald assumed coverage on shares of Arrowhead Research Corp. in a report on Wednesday, August 17th. They issued a “buy” rating and a $15.00 price target for the company. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $10.11.

The stock’s market capitalization is $447.12 million. The company has a 50-day moving average of $6.74 and a 200-day moving average of $5.80.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/arrowhead-research-corp-arwr-trading-4-2-higher.html

Arrowhead Research Corp. (NASDAQ:ARWR) last announced its earnings results on Tuesday, August 9th. The company reported ($0.32) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.05. The company earned $39.58 million during the quarter, compared to analyst estimates of $0.05 million. Arrowhead Research Corp. had a negative net margin of 48,980.81% and a negative return on equity of 100.50%. Arrowhead Research Corp.’s revenue was down 68.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.27) earnings per share. Equities research analysts forecast that Arrowhead Research Corp. will post ($1.31) earnings per share for the current year.

In other Arrowhead Research Corp. news, CFO Kenneth Allen Myszkowski sold 6,900 shares of the stock in a transaction dated Tuesday, August 23rd. The shares were sold at an average price of $8.00, for a total transaction of $55,200.00. Following the completion of the transaction, the chief financial officer now owns 128,789 shares of the company’s stock, valued at $1,030,312. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 3.90% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Moors & Cabot Inc. raised its position in Arrowhead Research Corp. by 0.6% in the second quarter. Moors & Cabot Inc. now owns 36,270 shares of the company’s stock valued at $190,000 after buying an additional 200 shares during the last quarter. ProShare Advisors LLC raised its position in Arrowhead Research Corp. by 1.2% in the second quarter. ProShare Advisors LLC now owns 52,038 shares of the company’s stock valued at $277,000 after buying an additional 616 shares during the last quarter. California State Teachers Retirement System raised its position in Arrowhead Research Corp. by 0.7% in the second quarter. California State Teachers Retirement System now owns 126,906 shares of the company’s stock valued at $675,000 after buying an additional 852 shares during the last quarter. BlackRock Advisors LLC raised its position in Arrowhead Research Corp. by 4.6% in the second quarter. BlackRock Advisors LLC now owns 27,943 shares of the company’s stock valued at $149,000 after buying an additional 1,232 shares during the last quarter. Finally, Nationwide Fund Advisors raised its position in Arrowhead Research Corp. by 4.6% in the second quarter. Nationwide Fund Advisors now owns 38,161 shares of the company’s stock valued at $203,000 after buying an additional 1,684 shares during the last quarter. 33.92% of the stock is owned by institutional investors and hedge funds.

Arrowhead Research Corp. Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.

5 Day Chart for NASDAQ:ARWR

Receive News & Ratings for Arrowhead Research Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Research Corp. and related companies with MarketBeat.com's FREE daily email newsletter.